Takeda Enlists Real World Evidence To Boost Marketed Entyvio
Japan’s Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.
You may also be interested in...
J&J's Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL-23 inhibitor for Crohn's disease, which hits a similar target as two key assets in J&J's immunology portfolio: Stelara and the Phase III biologic guselkumab.
Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.
Top-line data from a second patient group, asthmatics, in the Salford Lung Study indicate that switching from usual therapy to GSK’s’s Relvar Ellipta improves symptoms, but the results may not be enough to encourage switching before generic Seretide/Advair takes hold.